E-resources
Peer reviewed
-
Komrokji, Rami; Volpe, Virginia; Chan, Onyee; Al Ali, Najla; Swoboda, David; Kuykendall, Andrew; Padron, Eric; Sallman, David A.
Blood, 09/2021, Volume: 138, Issue: 11Journal Article
Komrokji et al examined the proposed international working group proposal to designate SF3B1-mutant myelodysplastic syndrome (MDS) as a unique disease entity, using a single-institution validation cohort of 1779 MDS patients, of whom 320 harbored SF3B1 mutations. They confirmed the demographics of older age, low-risk disease, ring sideroblasts, and low blast percentage. They further confirmed better overall survival that is negatively impacted in those patients with concomitant mutations, high variant allele fraction, and increased blast percentage.
